An Official Journal of ISoP


Call For Submissions for the First Issue of Quantitative Medicine

Quantitative Medicine is the first journal launched by the International Society of Pharmacometrics (ISoP)—a bold step forward in advancing innovation at the intersection of data, drug development, and therapeutics. Whether you're  a researcher, regulator, modeler, or clinician, Quantitative Medicine is your new home for rigorous, high-impact work that shapes the future of drug development. Submit your manuscript by December 31, 2025. 

 Explore the Journal                    Submit Your Research

About the Journal

Quantitative Medicine (QM) is a pioneering, fully open-access online journal devoted to advancing the development and application of quantitative methods in medicine. We have adopted the term “Quantitative Medicine” as a more inclusive reflection of the discipline that brings together the scientists, practitioners, and decision-makers engaged in the application of quantitative methods in the fields of clinical pharmacology, pharmacy, pharmacology and toxicology, translational sciences, medicine, drug discovery and development, regulatory assessment, health economics and outcomes research.

As the first official journal of ISoP, QM is grounded in our commitment to fostering scientific excellence and global collaboration in our field. This journal will serve as a platform to disseminate rigorous, innovative, and impactful research to inform drug discovery, development, regulatory decision-making, and pharmacotherapy. The journal will feature a multitude of formats for communicating novel quantitative methods, drug development and regulatory applications, perspectives, reviews, and tutorials throughout the life-cycle of drug development and clinical practice globally. The inaugural issue will provide a flavor of what this flagship journal of ISoP is intended to be.

Our Commitment to Scientific Excellence

ISoP champions a scientific culture rooted in transparency, rigor, and collaboration. QM reflects our commitment to data-driven insights and impact. Publishing with QM means joining a movement toward more transparent, impactful, and data-driven science. We stand for:

  • Data Driven Insights
  • Peer Reviewed Rigor
  • Global Collaboration
  • Therapeutic Impact

Aims & Scope

This cross-disciplinary journal is devoted to advancing the development and application of quantitative methods in medicine. It fosters global innovation and collaboration among scientists focused on the development, regulatory assessment, and therapeutic use of medicines.

QM showcases a diverse range of scientific content, including but not limited to:

  • Pharmacometrics: Pharmaco-statistical, mechanistic, and systems biology/pharmacology modeling.
  • Simulation-Based Approaches: Clinical trial simulations and digital twins.
  • AI/ML and Informatics: Applications of artificial intelligence, machine learning, and data science.
  • Integrated Evidence Synthesis: Model-based meta-analyses, causal inference, real-world evidence, network analyses, and health economics and outcomes research.

It highlights contributions such as:

  • Development of novel methods and tools
  • Standalone or integrated applications
  • Insights from applied quantitative approaches for decision and information analysis
  • Best practices and tutorials
  • Regulatory perspectives and considerations

Additional Information

About ScienceOpen

ScienceOpen is ISoP’s publishing partner, powering Quantitative Medicine on its open-access discovery platform. As an independent startup based in Berlin and Boston, ScienceOpen helps authors share research, boost visibility, and earn recognition through transparent metrics and peer review. 

Learn More

Meet the Editors

Raj Madabushi

Co-Founding Editor-in-Chief

Rajanikanth (Raj) Madabushi has over 15 years of regulatory experience. He currently serves as the Associate Director, Guidance and Scientific Policy in the Immediate Office of Office of Clinical Pharmacology.  Dr. Madabushi plays an instrumental role in the FDA’s PDUFA MIDD initiative and is the CDER Point-of-Contact for the MIDD Paired Meeting Program. Dr. Madabushi is also involved in global harmonization activities as the Rapporteur for ICH M12 Expert Working Group – Drug Interaction Studies. Dr. Madabushi received his Ph.D. in Pharmaceutical Sciences from Birla Institute of Technology and Sciences (BITS), Pilani, India.

Pavan Vaddady

Co-Founding Editor-in-Chief

Pavan Vaddady currently serves as an Executive Director, Quantitative Pharmacology & Pharmacometrics - Oncology at Merck & Co., Inc., where he leads a team of quantitative clinical pharmacologists advancing Merck’s oncology portfolio. During his career, he led several early and late-stage development programs across multiple therapeutic areas both as a clinical pharmacologist and a pharmacometrician and applied model informed approaches to impact key drug discovery and development decisions. Prior to his current role, he was the Head of Advanced Pharmacometrics, Quantitative Clinical Pharmacology at Daiichi Sankyo, Inc., where he led a global team of scientists working on advanced modeling projects involving multiple oncology assets. Pavan is passionate about teaching and mentoring colleagues and currently holds the position of Adjunct Professor at the University of Tennessee Health Science Center. He is also an elected Member of the Board of Trustees at the International Society of Pharmacometrics (ISoP).